Halozyme Therapeutics HALO Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The official record: Halozyme Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Halozyme Therapeutics's total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Halozyme Therapeutics's total equity?
- Halozyme Therapeutics (HALO) reported total equity of $219.64M in Q1 2026.
- How has Halozyme Therapeutics's total equity changed year-over-year?
- Halozyme Therapeutics's total equity decreased by 54.5% year-over-year, from $482.27M to $219.64M.
- What is the long-term trend for Halozyme Therapeutics's total equity?
- Over 5 years (2020 to 2025), Halozyme Therapeutics's total equity has grown at a -20.2% compound annual growth rate (CAGR), from $151.05M to $48.81M.
- What does total equity mean?
- The total value of the company belonging to shareholders after all debts are paid.
- How do you interpret total equity?
- An increasing trend generally indicates growth in company value and retained earnings, while a decreasing trend may signal losses or aggressive share buybacks.
- How does total equity compare across companies?
- Used to calculate return on equity (ROE) and assess the company's overall financial cushion.